GeneDx Holdings Q3 2026 earnings

WGS · 2026-11-09 16:10 AMC ET · 8-K on SEC

Revenue growth and margin expansion drive adjusted profitability, though GAAP losses remain.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$123.1M+5%+7.6%Ex. 99.1, income statement
EPS (GAAP)-$0.41-0.14+0.40Ex. 99.1, income statement
EPS (adjusted)$0.28-0.25+0.27Ex. 99.1, income statement
Net income-$12.3M-$4.7M+$8.2MEx. 99.1, income statement
Adj. EBITDA$8.7M-$7.5M+$8.5MEx. 99.1, income statement
Adj. EBITDA margin7.1%-6.4 pp+6.9 ppEx. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Whole exome, whole genome$110.4M+12%89.7%Volume +25% YoY
Other panels$9.7M-16%7.9%—
Data information$2.8M+22%2.3%—
Software and interpretation services$0.2M-89%0.2%—

Margins and costs

  • Gross margin 72% (70% Q2, +2 pp)
  • Operating expenses $79.4M (+5% YoY)
  • One-offs in the quarter Impairment loss $31.3M; Loss on extinguishment of debt $6.6M; Change in fair value of financial liabilities $2.8M; Legal reserves $0.8M
  • Effective tax rate 0.2% (prior-year 0.0%, year-to-date 0.1%)
  • Non-GAAP bridge Adds back depreciation and amortization, stock-based compensation, restructuring costs, and other non-core items.

KPIs

MetricActualPrior quarterPrior yearChange
Exome and genome volume32,13430,78525,702+4.4% QoQ, +25% YoY
Exome and genome revenue$110.4M$100.3M$98.9M+10% QoQ, +12% YoY
Adjusted gross margin72%70%74%+2 pp QoQ, -2 pp YoY
Cash, cash equivalents, marketable securities and restricted cash$171.1M$188.0M$133.5M-9% QoQ, +28% YoY

Guidance

MetricGuidePrior guideChange
Full year 2026 revenue$475 to $490M$475 to $490MNo change
Exome and genome volume growthAt least 30%At least 30%No change
Fourth quarter 2026 revenueNot providedNot providedN/A

What drove it

  • Revenue story Exome and genome revenue grew 12% YoY and 10% QoQ; total revenue grew 5% YoY and 7.6% QoQ.
  • EPS story Adjusted EPS improved $0.27 QoQ and $0.53 YoY driven by margin expansion and lower operating expenses.
  • One-off check Impairment loss $31.3M (non-recurring), Loss on extinguishment of debt $6.6M (non-recurring), Change in fair value of financial liabilities $2.8M (non-recurring), Legal reserves $0.8M (non-recurring).

The good

  • Adjusted gross margin expanded to 72%
  • Adjusted net income turned positive to $8.6M
  • Exome and genome volume grew 25% YoY

The bad

  • Other panels revenue declined 16% YoY
  • Software and interpretation services revenue declined 89% YoY
  • Adjusted EBITDA margin remains low at 7.1%

The ugly

  • none

Open questions

  • What is the specific revenue guidance for Q4 2026?
  • What caused the 89% decline in software and interpretation services revenue?
  • What caused the 16% decline in other panels revenue?
Full release

GeneDx Holdings (WGS) earnings release, November 9, 2026

GeneDx Holdings Corp. (WGS) · Form 8-K, Item 2.02 · Filed · SEC filing

GeneDx Reports Third Quarter 2026 Financial Results

• Reported third quarter 2026 revenue of $123.1 million, including $110.4 million in exome and genome revenue

• Reported exome and genome volume growth of 25% year-over-year with accession growth of 28% year-over-year

• Expanded adjusted gross margin

Financial statements

Income Statement

Volume & Revenue

3Q262Q261Q264Q253Q25
Volumes
Whole exome, whole genome32,13430,78527,48827,76125,702
Other panels26,52432,05727,72931,28134,514
Total58,65862,84255,21759,04260,216
Revenue ($ millions)
Whole exome, whole genome110.4100.390.610498.9
Other panels9.711.610.713.314.6
Data information2.82.30.82.61.5
Software and interpretation services0.20.20.21.11.7
Total123.1114.4102.3121116.7

Income Statement

Three months ended September 30, 2026 — Unaudited Select Financial Information

Three months ended September 30, 2026 – ReportedThree months ended September 30, 2026 – Depreciation and amortizationThree months ended September 30, 2026 – Stock-based compensationThree months ended September 30, 2026 – Restructuring costsThree months ended September 30, 2026 – Other(2)Adjusted
Diagnostic test revenue120,059120,059
Other revenue3,0423,042
Total revenue123,101123,101
Cost of services37,041-1,687-371-1834,965
Gross profit86,0601,6873711888,136
Gross margin69.971.6
Research and development17,366-430-1,5495115,438
Selling, general and administrative79,122-4,778-6,333-900-3,11863,993
(Loss) income from operations-10,4286,8958,2538673,1188,705
Interest expense, net-1,7791,779
Other income (expense), net-94-94
Income tax expense-2626
Net (loss) income-12,3276,8958,2538674,9238,611
Basic (loss) earnings per share(1)-0.410.29
Diluted (loss) earnings per share(1)-0.410.28

Income Statement

Three months ended September 30, 2025 — Unaudited Select Financial Information

Three months ended September 30, 2025 – ReportedThree months ended September 30, 2025 – Depreciation and amortizationThree months ended September 30, 2025 – Stock-based compensationThree months ended September 30, 2025 – Restructuring costsThree months ended September 30, 2025 – Change in FV of financial liabilitiesThree months ended September 30, 2025 – Other(2)Adjusted
Diagnostic test revenue113,523113,523
Other revenue3,2203,220
Total revenue116,743116,743
Cost of services32,216-1,374-21930,623
Gross profit84,5271,37421986,120
Gross margin72.473.8
Research and development19,829-242-1,74919618,034
Selling, general and administrative67,949-4,858-8,618-324-2,29751,852
(Loss) income from operations-3,2516,47410,5861282,29716,234
Interest expense, net-562562
Other income (expense), net-3,5753,401-2-176
Income tax expense-247247
Net (loss) income-7,6356,47410,5861283,4013,10416,058
Basic (loss) earnings per share(1)-0.270.56
Diluted (loss) earnings per share(1)-0.270.53

Income Statement

Three months ended June 30, 2026 — Unaudited Select Financial Information

Three months ended June 30, 2026 – ReportedThree months ended June 30, 2026 – Depreciation and amortizationThree months ended June 30, 2026 – Stock-based compensationThree months ended June 30, 2026 – Restructuring costsThree months ended June 30, 2026 – Change in FV of financial liabilitiesThree months ended June 30, 2026 – Other(2)Adjusted
Diagnostic test revenue111,886111,886
Other revenue2,5542,554
Total revenue114,440114,440
Cost of services36,202-1,726-561-4733,868
Gross profit78,2381,7265614780,572
Gross margin68.470.4
Research and development19,656-271-1,387-1,03616,962
Selling, general and administrative76,037-4,717-4,394-2,212-1,35363,361
(Loss) income from operations-17,4556,7146,3423,2951,353249
Interest expense, net-1,1851,185
Other (expense) income, net382-220162
Income tax benefit518-518
Net (loss) income-17,7406,7146,3423,295-2202,020411
Basic (loss) earnings per share(1)-0.60.01
Diluted (loss) earnings per share(1)-0.60.01

Income Statement

Three months ended September 30, — (in thousands, except share and per share amounts)

Three months ended September 30, – 2026Three months ended September 30, – 2025Nine months ended September 30, – 2026Nine months ended September 30, – 2025
Revenue
Diagnostic test revenue120,059113,523333,244299,382
Other revenue3,0423,2206,5517,168
Total revenue123,101116,743339,795306,550
Cost of services37,04132,216107,28692,645
Gross profit86,06084,527232,509213,905
Research and development17,36619,82956,82647,485
Selling, general and administrative79,12267,949229,750165,262
Impairment loss31,287
(Loss) income from operations-10,428-3,251-85,3541,158
Non-operating expense, net
Change in fair value of financial liabilities-3,4012,760-2,320
Interest expense, net-1,779-562-3,681-2,019
Loss on extinguishment of debt-6,565

Balance Sheet

December 31, 2025 — (in thousands, except share and per share amounts)

September 30, 2026 (Unaudited)December 31, 2025
Current assets:
Cash and cash equivalents96,139104,997
Marketable securities73,97966,285
Accounts receivable92,13174,370
Inventory, net21,70313,951
Prepaid expenses and other current assets12,9438,685
Total current assets296,895268,288
Operating lease right-of-use assets32,40423,412
Property and equipment, net53,53145,693
Goodwill1,64113,520
Intangible assets, net137,732168,481
Other assets(1)4,2814,316
Total assets526,484523,710
Current liabilities:
Accounts payable and accrued expenses32,42657,645
Short-term lease liabilities5,8234,404
Other current liabilities33,15446,859
Total current liabilities71,403108,908
Long-term debt, net of current portion146,22948,176
Long-term lease liabilities63,33256,046
Other liabilities711,641
Deferred taxes760757
Total liabilities281,795215,528
Stockholders’ Equity:
Class A common stock33
Additional paid-in capital1,711,6751,680,738
Accumulated deficit-1,466,878-1,373,495
Accumulated other comprehensive (loss) income-111936
Total stockholders’ equity244,689308,182
Total liabilities and stockholders’ equity526,484523,710

Cash Flow

Nine months ended September 30, — (in thousands)

Nine months ended September 30, – 2026Nine months ended September 30, – 2025
Operating activities
Net loss-93,383-3,355
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization expense20,41818,343
Stock-based compensation expense23,59122,382
Change in fair value of financial liabilities-2,7602,320
Deferred tax expense405448
Legal reserves810
Change in third party payor reserves-1,3708,746
Loss on extinguishment of debt6,565
Impairment loss31,287
Other3,6112,534
Change in operating assets and liabilities:
Accounts receivable-17,982-22,799
Inventory-7,823-72
Accounts payable and accrued expenses-19,3085,185
Other assets and liabilities-15,2391,827
Net cash (used in) provided by operating activities-71,98836,369
Investing activities
Acquisition of business, net of cash acquired-33,195
Purchases of marketable securities-40,859-36,535
Proceeds from sales of marketable securities3,172
Proceeds from maturities of marketable securities29,17533,955
Purchases of property and equipment and development of internal-use software-21,791-14,670
Net cash used in investing activities-30,303-50,445
Financing activities
Proceeds from long term debt, net of issuance costs146,027
Proceeds from offerings, net of issuance costs25,568
Proceeds from issuance of common stock from securities purchase agreement5,000
Proceeds from issuance of common stock from subscription agreements476
Proceeds from issuance of common stock pursuant to employee stock purchase plan1,7931,262
Exercise of stock options58982
Repayment of long-term debt, including prepayment penalty - Perceptive-54,000
Repayment and principal payments for long-term debt - DECD-4,447-906
Finance lease principal payments-1,473-2,074
Net cash provided by financing activities93,43424,832
Net (decrease) increase in cash, cash equivalents and restricted cash-8,85710,756

(1) to 72% and adjusted net income

(1) to $8.6 million

• Reiterating full year 2026 revenue guidance of $475 to $490 million

• Hosting conference call today at 4:30 p.m. ET

GAITHERSBURG, Md., November 9, 2026 — GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the third quarter of 2026.

“Our Q3 results reflect profitable execution in a growing market, as we translate the rising demand for exome and genome testing into durable revenue growth,” said Katherine Stueland, CEO of GeneDx. “Our priorities are clear: improve the economics of our testing, expand utilization, and deliver leading products at scale. By uniting these priorities with our clinical expertise and differentiated exome and genome capabilities, we are bringing life-changing answers to more families.”

Third Quarter 2026 Financial Results (Unaudited)

(1)

Revenue

• Revenue grew to $123.1 million, an increase of 5% year-over-year.

• Exome and genome test revenue grew to $110.4 million, an increase of 12% year-over-year.

Exome and genome volume

• Exome and genome test result volume grew to 32,134, an increase of 25% year-over-year, with accession growth of 28% year-over-year.

Gross margin

• Adjusted gross margin of 72% in the third quarter of 2026 is up from 70% in the second quarter of 2026 and compares to 74% in the third quarter of 2025.

◦ GAAP gross margin was 70%.

Operating expenses

• Adjusted total operating expenses were $79.4 million, representing 65% of revenue.

◦ Total GAAP operating expenses were $96.5 million.

Net income

• Adjusted net income was $8.6 million, up $8.2 million from the second quarter of 2026 and compared to adjusted net income of $16.1 million in the third quarter of 2025.

◦ GAAP net loss was $12.3 million.

Cash position

• Cash, cash equivalents, marketable securities and restricted cash was $171.1 million as of September 30, 2026.

(1)

Adjusted gross margin, adjusted total operating expenses and adjusted net income are non-GAAP financial measures. See appendix for a reconciliation of GAAP to non-GAAP figures presented.

GeneDx 2026 Guidance

GeneDx has updated its 2026 guidance and has provided guidance for the fourth quarter of 2026. Management expects GeneDx to deliver:

Third Quarter 2026 and Recent Business Highlights

Strategic Expansion and Market Leadership

• Announced genome testing portfolio enhancement with long-read whole genome sequencing, reflecting GeneDx's continued focus on genome innovation to expand diagnostic capabilities and deliver more answers to more patients.

• Launched additional customer experience features, including simplified test reports, easy ordering, and report guides to simplify genomic testing from ordering through understanding and communicating results.

• Launched a new online offering designed to expand accessibility of exome testing for pediatric patients with global developmental delay (GDD), intellectual disability (ID) or epilepsy by enabling families to initiate genetic testing online and connect with licensed healthcare providers who can review medical information, order testing, and deliver results without requiring traditional in-person visits.

• Collaborated with Mirum Pharmaceuticals to launch a sponsored testing program, providing no-cost exome testing for eligible patients with unexplained cholestasis, early onset cataracts, or suspected or confirmed peroxisome biogenesis disorder–Zellweger spectrum disorder (PBD-ZSD).

• Partnered with Beren Therapeutics P.B.C. to launch the NPC GenomeComplete Sponsored Testing Program, providing no-cost comprehensive genome sequencing for eligible pediatric patients with clinical findings, family history, or biomarker evidence suggestive of Niemann-Pick Disease Type C (NPC).

Expanded Coverage for Exome and Genome

• Expanded the number of state Medicaid programs covering whole genome sequencing to 25 with the addition of Arkansas and Utah Medicaid.

• Appointed Nicole Maassen, J.D. as Chief Patient Access Officer to lead Market Access and Government Affairs with a focus on advancing payer partnerships, building upon government relations efforts, and translating positive coverage policies into timely access for children who need testing.

Innovation and Clinical Leadership

• Published new data in collaboration with the clinical genetics team at Seattle Children’s demonstrating that implementing first-tier rapid genome sequencing (rGS) broadly across inpatient pediatric care units improves diagnostic rates, patient outcomes, and operational efficiency within health systems.

• Presented 27 scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are advancing scientific discovery, earlier diagnosis and more precise care. GeneDx research highlighted:

◦ Scaling genomic interpretation with AI and machine learning: A GeneDx-led platform presentation explores machine learning to prioritize relevant copy number variants (CNVs), reflecting the company’s human-first, human-last approach to leveraging AI decision support tools in exome and genome sequencing analysis.

◦ Advancing exome and genome sequencing as standard of care: Research from more than 100,000 individuals with autism examines factors influencing molecular diagnostic yield, adding evidence to support broad genomic testing for complex neurodevelopmental conditions.

◦ ... (truncated)t-line exome and genome sequencing.

◦ Accelerating gene discovery: Nine abstracts using GeneDx Infinity™, GeneMatcher and global research collaborations to identify novel disease-associated genes and expand understanding of developmental and neurodevelopmental disorders.

• Demonstrated progress toward making genomic newborn screening a scalable and accessible part of proactive healthcare at the International Consortium on Newborn Sequencing (ICoNS) conference, including new findings from the GUARDIAN study, which has enrolled 30,000 newborns with a 72.3% parental participation rate, demonstrating the feasibility and clinical value of genomic newborn screening across diverse populations.

• Partnered with the BRIDGES-NBS initiative to begin enrollment in Oregon as part of the nation's first coordinated, multi-state genomic newborn screening study. GeneDx serves as the integrated laboratory partner, providing genome sequencing and interpretation to screen up to 30,000 newborns for more than 700 actionable genetic conditions over two years.

Webcast and Conference Call Details

GeneDx will host a conference call today, November 9, 2026, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/.

Non-GAAP Financial Measures

GeneDx believes non-GAAP measures are useful in evaluating its operating performance. GeneDx uses this supplemental information to evaluate its ongoing operations and for internal planning and forecasting purposes. GeneDx believes that non-GAAP financial information, when taken collectively with its GAAP financial information, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Reconciliations of non-GAAP financial measures to the most directly comparable financial results as determined in accordance with GAAP are included at the end of this press release following the accompanying financial data. We define non-GAAP financial measures as GAAP measures, excluding certain items such as stock-based compensation expense, depreciation and amortization, restructuring costs, changes in the fair value of financial liabilities, non-core lease costs, and other expenses that the Company believes are not indicative of its ongoing operations. A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of expenses that may be incurred in the future. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures and not rely on any single financial measure to evaluate our business.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our future performance and our market opportunity, including our expectations for full year and fourth quarter 2026 revenue, exome and genome revenue and test volumes, adjusted gross margin and adjusted net income. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate,

(iv) future expansion of insurance coverage for exome and genome testing, and (v) the anticipated impacts of regulatory reimbursement changes. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year... (truncated)mation, future events, or otherwise. We do not give any assurance that we will achieve our expectations.

About GeneDx

GeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx™ and GenomeDx™ tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity also fuels discovery for biopharma, with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,100 research publications, GeneDx is building the network that will drive the future of genomic precision medicine. For more information, visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.

Investor Relations Contact:

Investors@GeneDx.com

Media Contact:

Press@GeneDx.com

Volume & Revenue

Unaudited Select Financial Information

(1)

Basic and diluted reported loss per share and Basic adjusted earnings per share are calculated based on 29,880,144 weighted average shares outstanding and Diluted adjusted earnings per share is calculated based on 30,756,054 weighted average shares outstanding for the three months ended September 30, 2026. Basic and diluted reported loss per share and Basic adjusted earnings per share are calculated based on 28,797,730 weighted average shares outstanding and Diluted adjusted earnings per share is calculated based on 30,152,510 weighted average shares outstanding for the three months ended September 30, 2025.

(2)

Other represents interest expense, net, income tax expense, non-core lease costs, and costs related to legal reserves for all periods presented. For the three months ended September 30, 2026, Other also includes third party advisor fees related to our Revenue Cycle Transformation. For the three months ended September 30, 2025, Other also includes transaction costs incurred in connection with the acquisition of Fabric Genomics.

Unaudited Select Financial Information

(1)

Basic and diluted reported loss per share and Basic adjusted earnings per share are calculated based on 29,710,139 weighted average shares outstanding and Diluted adjusted earnings per share is calculated based on 30,144,132 weighted average shares outstanding for the three months ended June 30, 2026.

(2)

For the three months ended June 30, 2026, Other represents interest expense, net, income tax benefit, non-core lease costs, and costs related to legal reserves.

GeneDx Holdings Corp.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

(1)

Other assets includes $1.0 million of restricted cash as of both September 30, 2026 and December 31, 2025.

GeneDx Holdings Corp.

Condensed Consolidated Statements of Operations (Unaudited)

(in thousands, except share and per share amounts)

GeneDx Holdings Corp.

Condensed Consolidated Statements of Cash Flows (Unaudited)

(in thousands)

(1)

Cash, cash equivalents and restricted cash as of September 30, 2026 excludes marketable securities of $74.0 million.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · GeneDx Holdings earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.